Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam

Future Microbiology

Volumn 12, Issue 14, 2017, Pages 1323-1326

  Xipell, Marc ^a   Bodro, Marta ^a   Marco, Francesc ^a   Martínez, José A ^a   Soriano, Alex ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ceftolozane tazobactam; clinical experience; multidrug resistant organisms; Pseudomonas aeruginosa; severe infections

Indexed keywords

AMIKACIN; CEFTAZIDIME; CEFTOLOZANE; COLISTIN; MEROPENEM; TAZOBACTAM; TEICOPLANIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ADULT; AGED; ANTIBIOTIC THERAPY; AORTIC VALVE REPLACEMENT; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CANCER CHEMOTHERAPY; CANCER SURGERY; CARDIOVASCULAR RISK; CASE REPORT; CHOLECYSTECTOMY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; EXTENSIVELY DRUG RESISTANT PSEUDOMONAS AERUGINOSA; FEMALE; FEVER; HEPATITIS C; HUMAN; KLEBSIELLA PNEUMONIAE; LABORATORY TEST; LIVER ABSCESS; LIVER CIRRHOSIS; LIVER GRAFT; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT PSEUDOMONAS AERUGINOSA INFECTION; NONHUMAN; PERCUTANEOUS DRAINAGE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RELAPSE; SCLEROSING CHOLANGITIS; TREATMENT DURATION; VERY ELDERLY; ANALOGS AND DERIVATIVES; DRUG EFFECT; DRUG POTENTIATION; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; FEMALE; HUMANS; MALE; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 85034060966     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2017-0018     Document Type: Article

References (12)

1. Morata L, Cobos-Trigueros N, Martínez JA et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 56(9), 4833-4837 (2012).
2. Huwaitat R, Mccloskey AP, Gilmore BF, Laverty G. Potential strategies for the eradication of multi-drug resistant Gram-negative bacterial infections. Future Microbiol. 11, 955-972 (2016).
3. Amin AN, Deruelle D. Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA. Future Microbiol. 10(6), 1049-1062 (2015).
4. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation ?-lactam/?-lactamase inhibitor combinations. Clin. Infect. Dis. 63(2), 234-241 (2016).
5. Buehrle DJ, Shields RK, Chen L et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob. Agents Chemother. 60(5), 3227-3231 (2016).
6. Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J. Antimicrob. Chemother. 72(5), 1386-1395 (2017).
7. Magiorakos A, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268-281 (2011).
8. Tato M, García-Castillo M, Bofarull AM, Cantón R, CENIT Study Group. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study. Int. J. Antimicrob. Agents 46(5), 502-510 (2015).
9. Miller B, Popejoy MW, Hershberger E, Steenbergen JN, Alverdy J. Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, Phase III ceftolozane-tazobactam study. Antimicrob. Agents Chemother. 60(7), 4387-4390 (2016).
10. Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 61(5), 853-855 (2015).
11. Hernández-Tejedor A, Merino-Vega CD, Martín-Vivas A et al. Successful treatment of multidrug-resistantPseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam. Infection 45(1), 115-117 (2016).
12. VanScoy BD, Mendes RE, Castanheira M, et al. Relationship between ceftolozane-tazobactamexposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiberinfection model. Antimicrob. Agents Chemother. 58(10), 6024-6031 (2014).